Analyst Rating Update on Novartis AG (NVS)

Novartis AG (NVS) has an average broker rating of 2.26, which is interpreted as a Buy, as rated by 9 equity analysts. Nonetheless, 4 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 4 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.

Novartis AG (NVS) : Average target price received by Novartis AG (NVS) is $92.75 with an expected standard deviation of $14.86. The most aggressive target on the stock is $115, whereas the most downbeat target is $84. 4 financial analysts are currently covering the stock.

For the current week, the company shares have a recommendation consensus of Buy.


Novartis AG (NYSE:NVS): The stock opened at $81.79 on Wednesday but the bulls could not build on the opening and the stock topped out at $82.48 for the day. The stock traded down to $81.78 during the day, due to lack of any buying support eventually closed down at $82.40 with a loss of -0.68% for the day. The stock had closed at $82.96 on the previous day. The total traded volume was 1,315,833 shares.

Novartis AG is a holding company that, through its subsidiaries, is engaged in development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines, eye care, generic pharmaceuticals, preventive vaccines and over-the-counter (OTC) products. The Companys segments include Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals, and Consumer Health, which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia, Exjade, Galvus, Exforge and Voltaren, among others. Its Sandoz products include Valsartan (Diovan), Cyclophosphamide injection and AirFluSal Forspiro, among others. Its OTC offers readily available consumer medicine. The Company operates Admune Therapeutics as a wholly owned subsidiary.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.